Literature DB >> 2717273

Child mortality related to seroconversion or lack of seroconversion after measles vaccination.

P Aaby1, I R Pedersen, K Knudsen, M C da Silva, C H Mordhorst, N C Helm-Petersen, B S Hansen, J Thårup, A Poulsen, M Sodemann.   

Abstract

When blood samples were analyzed for seroconversion after measles vaccination, it was discovered that the vaccine had been ineffective for a certain period. During the 2 years between vaccination and the time of seroanalysis, nonseroconverters had a significantly higher mortality than seroconverters (P less than 0.05). The incidence of measles among nonseroconverters was 30% during the period. Between 9 months and 3 years of age, cumulative mortality was 15.1% for nonseroconverters and 4.5% for seroconverters. The difference in mortality was larger when high risk groups (twins, motherless children) were excluded from the analysis (P less than 0.01). The difference in mortality was particularly marked among children vaccinated in the age group 9 to 11 months. This as well as other community studies suggest that measles vaccination reduces child mortality from the age of vaccination by at least 30%.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Antibodies--analysis; Biology; Child Mortality; Communicable Diseases--prevention and control; Delivery Of Health Care; Demographic Factors; Developing Countries; Diseases; Evaluation; Examinations And Diagnoses; Guinea-bissau; Health; Health Services; Immunity; Immunization; Immunologic Factors; Incidence; Infant Mortality; Infections; Laboratory Examinations And Diagnoses; Measurement; Mortality; Physiology; Population; Population Dynamics; Portuguese Speaking Africa; Primary Health Care; Research Methodology; Vaccination; Western Africa

Mesh:

Substances:

Year:  1989        PMID: 2717273

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  14 in total

1.  Unexpected beneficial effects of measles immunisation. Measles vaccination may be marker for other health seeking behaviours.

Authors:  C Dalton
Journal:  BMJ       Date:  2000-04-01

2.  Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries.

Authors:  P Aaby; B Samb; F Simondon; A M Seck; K Knudsen; H Whittle
Journal:  BMJ       Date:  1995-08-19

3.  Nutritional status and delayed mortality following early exposure to measles.

Authors:  P Aaby; M Andersen; K Knudsen
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

Review 4.  Saving children's lives by vaccination.

Authors:  D Morley
Journal:  BMJ       Date:  1989 Dec 23-30

5.  Cell mediated immunity after measles in Guinea-Bissau: historical cohort study.

Authors:  S O Shaheen; P Aaby; A J Hall; D J Barker; C B Heyes; A W Shiell; A Goudiaby
Journal:  BMJ       Date:  1996-10-19

6.  Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa.

Authors:  I Kristensen; P Aaby; H Jensen
Journal:  BMJ       Date:  2000-12-09

7.  Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.

Authors:  Peter Aaby; Cesário L Martins; May-Lill Garly; Carlito Balé; Andreas Andersen; Amabelia Rodrigues; Henrik Ravn; Ida M Lisse; Christine S Benn; Hilton C Whittle
Journal:  BMJ       Date:  2010-11-30

8.  Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age.

Authors:  P Aaby; M Andersen; M Sodemann; M Jakobsen; J Gomes; M Fernandes
Journal:  BMJ       Date:  1993-11-20

9.  Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants.

Authors:  P Kiepiela; H M Coovadia; W E Loening; P Coward; G Botha; J Hugo; P J Becker
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

10.  The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy.

Authors:  Peter Aaby; Cesário L Martins; May-Lill Garly; Amabelia Rodrigues; Christine S Benn; Hilton Whittle
Journal:  BMJ Open       Date:  2012-07-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.